Effect of Nicotine on Cytokine Production by Human Mononuclears: Perspective of COVID-19

Authors

  • Waghmode Meghmala S Assistant Professor, Department of Microbiology, P.D.E.A.’s Annasaheb Magar Mahavidyalaya, Hadapsar, Pune, Maharashtra, India
  • Divekar Akshay B Research Scholar, Department of Microbiology, P.D.E.A.’s Annasaheb Magar Mahavidyalaya, Hadapsar, Pune, Maharashtra, India
  • Dhasade Akshay Y Research Scholar, Department of Microbiology, P.D.E.A.’s Annasaheb Magar Mahavidyalaya, Hadapsar, Pune, Maharashtra, India
  • Mulani Mansurali K Research Scholar, Department of Microbiology, P.D.E.A.’s Annasaheb Magar Mahavidyalaya, Hadapsar, Pune, Maharashtra, India
  • Patil Neha N Professor & HOD, Department of Microbiology, P.D.E.A.’s Annasaheb Magar Mahavidyalaya, Hadapsar, Pune, Maharashtra, India

DOI:

https://doi.org/10.37591/rrjoi.v11i1.2382

Keywords:

nicotine, Cytokine, Immunity, Cancer, covid19

Abstract

Nicotine is present in the tobacco-containing products such as cigars, cigarettes, chewing tobacco, snus (an oral tobacco) and pipe tobacco. In Indian population, nicotine containing products are consumed by the 57% of population either in chewing form or smoking form. The correlation of nicotine and lung cancer in chronic smokers as well as nicotine consumption and COVID-19 incidence has to be justified. Hence current research was carried to study the effect of nicotine on cytokine production by peripheral blood mononuclear cells (PBMC’s). MACSPlex Cytokine12 assay was used for the estimation of cytokine after treatment of PBMC’s with the nicotine. Concentration of cytokines (IL 10, IL 12p70, IL 17, IFN α, IFN γ, GM CSF, IL 4, IL 5, IL 2 and IL 9) was found to be increased in the sample containing PBMC’s treated with the 20 µl of nicotine indicating that nicotine promotes PBMC’s for the secretion of IL 10, IL 12p70, IL 17, IFN α, IFN γ, GM CSF, IL 4, IL 5, IL 2 and IL 9 but it impedes the production of IL 6 and TNF α the important pro-inflammatory cytokines. IL 6 and TNF α are the important pro-inflammatory cytokines in COVID-19 infection being responsible to switch the infection from mild to a fatal one. The impeding characteristics of nicotine can be proposed to have potential of pharmaceutical nicotine as a future treatment option in COVID-19. The detailed studies are needed for developing nicotine patches as a prospective cytokine release syndrome (CRS) therapy for COVID-19 to combat this dreadful pandemic.

References

Reddy SS, Shaik Hakh. Estimation of nicotine content in popular Indian brands of smoking and chewing tobacco products. Indian J Dental Res. 2008; 19(2): 88–91p.

Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD and Najera Al. Cytokine Release Syndrome (CRS) and nicotine in COVID-19 patients: trying to calm the storm. Front Immunol. 2020; 11: 1359. DOI: 10.3389/fimmu. 2020. 01359

Ranta N, Turpeinen H, Oksanen A, Hämäläinen S, Huttunen R, Uusitalo-Seppälä R, et al. The plasma level of proprotein convertase furin in patients with suspected infection in the emergency room: a prospective cohort study. Scand J Immunol. 2015; 48(3): 173–177p.

Abdel Massih AF, Ye J, Kamel A, Mishriky F, Ismail HA, Ragab HA, et al. A multicenter consensus: A role of furin in the endothelial tropism in obese patients with COVID-19 infection. Obesity medicine. 2020; 19: 100281. Available at: https://doi.org/10.1016/j.obmed.2020.100281

Gomes JP, Watad A, Shoenfeld Y. Nicotine and autoimmunity: the lotus' flower in tobacco. Pharmacol Res. 2018; 128: 101–109p. doi: 10.1016/j.phrs.2017.10.005.

Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Belló I, Cilio CM, Wong FS, et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol. 2011; 163(1): 33–49p. doi:10.1111/j.1365-2249.2010.04272.x

St-Pierre S, Jiang W, Roy P, Champigny C, LeBlanc E, Morley BJ, et al. Nicotinic acetylcholine receptors modulate bone marrow-derived pro-inflammatory monocyte production and survival. PLoS One. 2016; 11: e0150230.

Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol. 2020; 21: 1146–1151p. Available at: https://doi.org/10.1038/s41590-020-0779-1

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20: 355–362p.

Chen LD, Zhang ZY, Wei XJ, Cai YQ, Yo WZ, Wang MH, et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir Res. 21, 201 (2020). Available at: https://doi.org/10.1186/s12931-020-01465-2.

Polosa R, Caci G. COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine. Internal Emerg Med. 2020; 15(5): 853–856p. Available at: https://doi.org/10.1007/s11739-020-02361-9.

Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369: m1966.

Downloads

Published

2021-04-16

Issue

Vol. 11 No. 1 (2021)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.